Evidence map›Paper›PMID 39360715›Full record

ArticleEmerging microbes & infections2024

Ad5-nCoV boosted vaccine and reinfection-induced memory T/B cell responses and humoral immunity to SARS-CoV-2: based on two prospective cohorts.

Aidibai Simayi, Yuxin Chen, Jinjin Chu, Huiyan Yu, Shihan Zhang, Changjun Bao, Fengcai Zhu, Hui Jin, Yuanfang Qin, Qian Zhen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aidibai SimayiDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, People's Republic of China.
Yuxin ChenDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing.
Jinjin ChuDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Huiyan YuDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Shihan ZhangDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, People's Republic of China.
Changjun BaoDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Fengcai ZhuDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Hui JinDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, People's Republic of China.
Yuanfang QinDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Qian ZhenDepartment of Acute Infectious Disease Control and Prevention, Changzhou Center for Disease Control and Prevention, Changzhou, People's Republic of China.
Yong LiuDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing.
Liguo ZhuDepartment of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we regularly followed two SARS-CoV-2 infected cohorts to investigate the combined effects of neutralizing antibodies (NAbs) and B and T cell profiles during the convalescent period. Ten infected participants in December 2022 were selected to assess the effects of an inhaled adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) booster on B cells and humoral immunity in the first cohort. To evaluate T cell responses, eight primary and 20 reinfection participants were included in the second cohort. Blood samples from all 38 participants were collected at 1-, 2-, and 6-months post-infection. In the first cohort, eighteen monoclonal antibodies (mAbs) with neutralizing activity from memory B cells (MBC) against SARS-CoV-2 mutants were obtained by high throughput single-B-cell cloning method, which lasted from 1- month to 6- month post infection. The overall number of mAbs from MBC in the boosted immunization group was higher than that in the nonboosted immunization group at 2-, and 6-months post-infection. In the second cohort, circulating T follicular helper cells (cTfh) and AIM

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesImmunity, HumoralReinfectionSARS-CoV-2AdenoviridaeAdultAntibodies, MonoclonalB-LymphocytesFemaleHumansImmunization, SecondaryImmunologic MemoryMaleAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesAd5-nCoV-boosted immunizationcellular immunityCOVID-19humoral immunityreinfection

Identifiers

PMID39360715
PMCPMC11529888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.